Irino

Irinotecan Hydrochloride Trihydrate, the active ingredient in Irino, is a topoisomerase I inhibitor presented as a sterile injectable solution for intravenous use. It is employed in the treatment of metastatic colorectal cancer and advanced colorectal cancer in adult patients.

GNH USA supplies Irino as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

Irino is a topoisomerase I inhibitor used in colorectal cancer therapy.

Metastatic colorectal cancer: improves overall survival when used in combination chemotherapy regimens. Advanced colorectal cancer: provides disease control in patients who have progressed on prior therapies. Colorectal cancer (FOLFIRI regimen): serves as the irinotecan component of standard combination protocols.

Adverse reactions may vary in frequency and severity.

Common Side Effects: - Diarrhea: often severe and may require antidiarrheal therapy. - Neutropenia: reduced white blood cell count increasing infection risk. - Nausea and vomiting: may be managed with antiemetics. - Alopecia: temporary hair loss during treatment. - Fatigue: generalized tiredness affecting daily activities. - Anemia: decreased red blood cell count causing weakness.

Serious or Rare Side Effects: - Febrile neutropenia: fever with low neutrophil count requiring urgent care. - Severe colitis: inflammation of the colon that can be life‑threatening. - Hepatotoxicity: liver enzyme elevations indicating potential liver injury. - Hypersensitivity reactions: rash, bronchospasm, or anaphylaxis. - Cardiac toxicity: rare arrhythmias or myocardial ischemia.

Patients should be monitored closely for known toxicities and appropriate supportive care.

Baseline blood counts: obtain complete blood count before each cycle. Renal and hepatic function: assess liver enzymes and creatinine to adjust dosing if needed. Concurrent infections: treat active infections before initiating therapy. Pregnancy and lactation: avoid use unless benefits outweigh potential fetal risks. Drug‑specific monitoring: watch for signs of severe diarrhea and neutropenia. Store at ambient temperature: keep in original container, protect from light and moisture.

Irinotecan may interact with several concomitant medications.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce irinotecan exposure. - Potent UGT1A1 inhibitors (e.g., atazanavir): can increase SN‑38 levels and toxicity.

Moderate Interactions (Monitor Closely): - Anticoagulants (warfarin, heparin): heightened bleeding risk due to thrombocytopenia. - Other myelosuppressive agents: additive bone‑marrow suppression. - Antiemetics containing metoclopramide: may alter gastric motility affecting drug absorption.